Podcast Summary

Podcast: Becker Private Equity & Business Podcast
Host: Scott Becker
Episode: GoodRx: Is it Today’s hims & hers?
Date: August 18, 2025

Episode Overview

In this episode, Scott Becker delves into the surging business of weight loss drugs, spotlighting two high-profile companies: GoodRx and Hims & Hers. He examines the impact of recent developments—including a significant price shift for Ozempic by Novo Nordisk—on business performance, share prices, and broader market trends in telehealth and the GLP-1 weight loss category.

Key Discussion Points & Insights

1. GoodRx’s Surge on Weight Loss Drug Deal

• GoodRx’s Stock Performance:

  • GoodRx stock is up 30% following their announcement of a deal to sell popular weight loss medications Ozempic and Wegovy.
  • Scott notes that this single business development sent the stock soaring, demonstrating the market’s strong interest in GLP-1 medications.

• Quote:

  “Goodrx is on a tier today. It's up 30% after cutting a deal to sell Ozempic and Wegovy.” (Scott Becker, 00:13)

2. Hims & Hers: From ED to Weight Loss Blockbuster

• Business Model Evolution:

  • Hims & Hers, originally known for telehealth-driven ED (erectile dysfunction) drug sales, has pivoted toward weight loss drugs, which has fueled explosive growth.
  • The company has seen tremendous stock performance over the past year due to its expansion into the telehealth weight loss space.

• Quote:

  “Originally it was famous for selling erectile dysfunction drugs. It then really compounded and grew incredibly based on the ability to sell these weight loss drugs through telehealth and more.” (Scott Becker, 00:28)

• Stock Performance:

  • Hims & Hers is up approximately 86% year-to-date.

• Quote:

  “Hims and hers is up 85% year to date for all of those.” (Scott Becker, 01:20)

3. Novo Nordisk’s Price Cut for Ozempic

• Major Announcement:

  • Novo Nordisk, the manufacturer of Ozempic (a leading GLP-1 drug), will cut prices for cash buyers in the U.S. by 50%.
  • The price drop is from approximately $1,000/month down to $500/month ($4.99 as mentioned for some users), aiming to respond to competitive and market pressures as the drug becomes more commoditized.

• Stock Impact:

  • Novo Nordisk’s stock has suffered, reportedly down more than 60% over the last year.

• Quote:

  “Novo Nordisk... announced today that they're going to cut the price for people that are buying directly their drug Ozempic... they're going to cut the price for cash buyers in half.” (Scott Becker, 00:51)

• Quote:

  “Yes, Novo Nordisk is going to offer Ozempic at first $4.99 a month to U.S. customers.” (Scott Becker, 02:00)

4. GLP-1 Weight Loss Category: Business Trend

• Market Dynamics:

  • Discussion centers around the commoditization of GLP-1 drugs as more retailers and telehealth platforms gain access to distribute them at lower prices.
  • The explosive growth of companies involved with GLP-1 drugs reflects intense consumer demand for new weight loss solutions.

• Personal Touch:

  • Scott candidly relates to the audience about the challenges of weight loss and the relevance of these business trends.

• Quote:

  “For all of us that struggle a little bit with weight loss and weight control. God bless us. And keeping an eye on it.” (Scott Becker, 01:24)

Notable Quotes & Timestamps

• GoodRx’s Surprise Growth:

  “Goodrx is on a tier today. It's up 30% after cutting a deal to sell Ozempic and Wegovy.” (Scott Becker, 00:13)

• Hims & Hers’s Strategic Shift:

  “It then really compounded and grew incredibly based on the ability to sell these weight loss drugs through telehealth.” (Scott Becker, 00:29)

• Price Drop Effects:

  “Novo Nordisk... they're going to cut the price for cash buyers in half... that that's going to be about $500 a month versus $1,000 a month.” (Scott Becker, 00:51)

• Weight Loss Struggles:

  “For all of us that struggle a little bit with weight loss and weight control. God bless us.” (Scott Becker, 01:24)

• Current Offering:

  “Yes, Novo Nordisk is going to offer Ozempic at first $4.99 a month to US customers.” (Scott Becker, 02:00)

Key Segment Timestamps

• 00:00 – 00:13: Introduction and GoodRx headline
• 00:13 – 00:40: GoodRx surge, Hims & Hers expansion
• 00:40 – 01:08: Novo Nordisk’s 60% drop and Ozempic price cut
• 01:08 – 01:30: Hims & Hers year-to-date performance and personal reflections on weight loss
• 01:30 – 02:00: GLP-1 commoditization and outro

Conclusion

Scott Becker succinctly connects the dots on how the booming demand for weight loss medications—particularly GLP-1 agonists like Ozempic and Wegovy—are reshaping the fortunes of both new and established players. GoodRx’s latest pivot mirrors the earlier success of Hims & Hers, while price competition heats up with moves from big pharma like Novo Nordisk. For investors, consumers, and those following telehealth or private equity, these fast-moving developments are shaping a dynamic new marketplace.